Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

AstraZeneca R&D chief Morrison makes unexpected exit

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

UPDATED: AstraZeneca R&D chief Briggs Morrison makes an unexpected exit

Briggs Morrison, the executive vice president for R&D at AstraZeneca and a major player in the pharma company's turnaround attempt over the past three years, is leaving the pharma giant, FierceBiotech has learned.

10X Genomics poaches David Jaffe from the Broad Institute

10X Genomics has lured David Jaffe away from the Broad Institute. Jaffe spent 15 years at Broad, during which time he developed methods for genome assembly and variant analysis.

Big data tells J&J that recent grads are more loyal than experienced hires

The "people analytics team" at drugmaker Johnson & Johnson used big data analysis techniques on employees to figure out whether hiring people with experience pays off better than picking up kids right out of college. The result is good news for all of those MBA still beating the bushes for a job.

Regulus CEO Xanthopoulos' abrupt exit alarms investors

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Fresh off Novartis consumer deal, GSK slices off 350 workers to hit cost-squeezing targets

Now that it's teamed up with Novartis' consumer health unit to form an industry-leading joint venture, GlaxoSmithKline's OTC business is bigger than ever. But its payroll is about to get smaller, with 350 layoffs hitting the operation.

Is Pozen prepping to sell out? Sudden CEO exit, new Irish subsidiary hint yes

Pozen has had its share of woes in recent months: Manufacturing problems at its contract supplier tanked new drug applications twice in a row, and Big Pharma partner Sanofi bailed on their development deal for the new-and-improved aspirins.

Betting on Pfizer merger--or CEO goodbye--traders go bullish on Glaxo

Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea. As Bloomberg reports, options traders are paying record prices for bullish GSK options--and this after the British drugmaker lost $11 billion off its market cap in less than three months.

Merck KGaA poaches Sanofi oncology exec Zhen Su

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

How well paid are pharma execs? Best in healthcare, survey shows

How does pharma executive pay compare with the rest of healthcare? Forbes columnist Dan Munro decided to find out--and the answer is that drugmakers pay their top managers more than in any other slice of the healthcare industry.